WO2009124330A3 - Behandlung von tumorerkrankungen - Google Patents

Behandlung von tumorerkrankungen Download PDF

Info

Publication number
WO2009124330A3
WO2009124330A3 PCT/AT2009/000136 AT2009000136W WO2009124330A3 WO 2009124330 A3 WO2009124330 A3 WO 2009124330A3 AT 2009000136 W AT2009000136 W AT 2009000136W WO 2009124330 A3 WO2009124330 A3 WO 2009124330A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumors
treatment
ace2
polypeptide
drug
Prior art date
Application number
PCT/AT2009/000136
Other languages
English (en)
French (fr)
Other versions
WO2009124330A2 (de
Inventor
Evelyne Janzek-Hawlat
Hans Loibner
Manfred Schuster
Bernhard Peball
Original Assignee
Apeiron Biologics Forschungs- Und Entwicklungsgesellschaft M.B.H.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeiron Biologics Forschungs- Und Entwicklungsgesellschaft M.B.H. filed Critical Apeiron Biologics Forschungs- Und Entwicklungsgesellschaft M.B.H.
Priority to JP2011503304A priority Critical patent/JP5650639B2/ja
Priority to NZ588435A priority patent/NZ588435A/xx
Priority to AU2009235931A priority patent/AU2009235931B2/en
Priority to ES09730771T priority patent/ES2425308T3/es
Priority to EP09730771.4A priority patent/EP2274005B1/de
Priority to DK09730771.4T priority patent/DK2274005T3/da
Priority to US12/937,029 priority patent/US8946162B2/en
Priority to PL09730771T priority patent/PL2274005T3/pl
Priority to CA2720616A priority patent/CA2720616C/en
Publication of WO2009124330A2 publication Critical patent/WO2009124330A2/de
Publication of WO2009124330A3 publication Critical patent/WO2009124330A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Beschrieben wird die Verwendung eines Polypeptids mit einer Angiotensin konvertierenden Enzym 2 (angiotensin Converting enzyme 2; ACE2)-Aktivität zur Herstellung eines Medikaments zur Behandlung von Tumorerkrankungen.
PCT/AT2009/000136 2008-04-09 2009-04-07 Behandlung von tumorerkrankungen WO2009124330A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2011503304A JP5650639B2 (ja) 2008-04-09 2009-04-07 腫瘍疾患の治療
NZ588435A NZ588435A (en) 2008-04-09 2009-04-07 Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)
AU2009235931A AU2009235931B2 (en) 2008-04-09 2009-04-07 Treatment of tumors
ES09730771T ES2425308T3 (es) 2008-04-09 2009-04-07 Tratamiento de enfermedades tumorales mediante enzima convertidora de angiotensina 2 (ACE2)
EP09730771.4A EP2274005B1 (de) 2008-04-09 2009-04-07 Behandlung von tumorerkrankungen durch angiotensin konvertierendes enzym 2 (ace2)
DK09730771.4T DK2274005T3 (da) 2008-04-09 2009-04-07 Behandling af tumorsygdomme med angiotensin konverterende enzym 2 (ACE2)
US12/937,029 US8946162B2 (en) 2008-04-09 2009-04-07 Treatment of tumors
PL09730771T PL2274005T3 (pl) 2008-04-09 2009-04-07 Leczenie chorób nowotworowych z użyciem konwertazy angiotensyny 2 (ace2)
CA2720616A CA2720616C (en) 2008-04-09 2009-04-07 Treatment of tumours

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0056608A AT506632A1 (de) 2008-04-09 2008-04-09 Behandlung von tumorerkrankungen
ATA566/2008 2008-04-09

Publications (2)

Publication Number Publication Date
WO2009124330A2 WO2009124330A2 (de) 2009-10-15
WO2009124330A3 true WO2009124330A3 (de) 2009-12-10

Family

ID=41130316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2009/000136 WO2009124330A2 (de) 2008-04-09 2009-04-07 Behandlung von tumorerkrankungen

Country Status (12)

Country Link
US (1) US8946162B2 (de)
EP (2) EP2644203A1 (de)
JP (1) JP5650639B2 (de)
AT (1) AT506632A1 (de)
AU (1) AU2009235931B2 (de)
CA (1) CA2720616C (de)
DK (1) DK2274005T3 (de)
ES (1) ES2425308T3 (de)
NZ (1) NZ588435A (de)
PL (1) PL2274005T3 (de)
PT (1) PT2274005E (de)
WO (1) WO2009124330A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
CA2875625C (en) * 2012-06-06 2021-06-22 Attoquant Diagnostics Gmbh Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
ES2732282T3 (es) * 2013-01-14 2019-11-21 Apeiron Biologics Ag Polipéptidos de ECA2 modificados
ES2761562T3 (es) * 2013-12-11 2020-05-20 Alterras Therapeutics Gmbh Composiciones y procedimientos para el tratamiento de enfermedades relacionadas con el sistema renina-angiotensina
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US20200188473A1 (en) * 2017-05-02 2020-06-18 Beth Israel Deaconess Medical Center, Inc. Combination therapy for cancer
CA3082610A1 (en) 2017-11-29 2019-06-06 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
US20230181759A1 (en) * 2020-04-01 2023-06-15 Washington University Compositions for treatment of viral respiratory infections and methods of use thereof
CN112626099A (zh) * 2020-09-29 2021-04-09 清华大学 使用原核细胞发酵表达血管紧张素转化酶2的方法
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2023102156A1 (en) 2021-12-03 2023-06-08 Wisconsin Alumni Research Foundation Mutant ace2 proteins and methods of using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000367A1 (en) * 2002-06-19 2003-12-31 University Health Network Ace2 activation for treatment of heart, lung and kidney disease and hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989363B1 (en) 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6610497B1 (en) 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
WO2003072059A2 (en) * 2002-02-27 2003-09-04 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
EP1374907A3 (de) 2002-06-24 2004-01-07 Ghanem Elias c/o Institut Jules Bordet Ghanem Arzneimittel Transport und Abgabesystem
EP1723962A1 (de) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Gebrauch der Hemmnisse des Renin-angiotensinsystems für die Behandlung der Lungenverletzungen
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000367A1 (en) * 2002-06-19 2003-12-31 University Health Network Ace2 activation for treatment of heart, lung and kidney disease and hypertension

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2008 (2008-04-01), LOIBNER HANS ET AL: "Development of recombinant human soluble angiotensin converting enzyme 2 (rkACE2) for cancer therapy", XP002549481, Database accession no. PREV200800488340 *
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 49, April 2008 (2008-04-01), 99TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; SAN DIEGO, CA, USA; APRIL 12 -16, 2008, pages 969, ISSN: 0197-016X *

Also Published As

Publication number Publication date
CA2720616A1 (en) 2009-10-15
EP2274005B1 (de) 2013-05-29
DK2274005T3 (da) 2013-08-19
US20110033524A1 (en) 2011-02-10
CA2720616C (en) 2016-08-09
AU2009235931A1 (en) 2009-10-15
JP2011516501A (ja) 2011-05-26
US8946162B2 (en) 2015-02-03
AU2009235931B2 (en) 2015-07-23
JP5650639B2 (ja) 2015-01-07
EP2274005A2 (de) 2011-01-19
EP2644203A1 (de) 2013-10-02
NZ588435A (en) 2012-10-26
WO2009124330A2 (de) 2009-10-15
ES2425308T3 (es) 2013-10-14
PL2274005T3 (pl) 2013-12-31
AT506632A1 (de) 2009-10-15
PT2274005E (pt) 2013-08-27

Similar Documents

Publication Publication Date Title
WO2009124330A3 (de) Behandlung von tumorerkrankungen
WO2007025613A3 (en) Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2008120098A3 (en) Peptide prodrugs
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2010083347A3 (en) Peptidomimetic macrocycles
WO2012048099A3 (en) Nanoparticle-loaded cells
UA106037C2 (uk) Модулятори ampk (амф-активованої протеїнкінази)
MX2011007930A (es) Conjugados de insulina cristalina.
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2011133875A3 (en) Metalloenzyme inhibitor compounds
WO2009089635A9 (en) Treating neurodegenerative diseases with progranulin (pgrn)
WO2008051805A3 (en) Triazolo-pyridazine protein kinase modulators
WO2008124849A3 (en) Pyrrolo-pyridine kinase modulators
WO2009014650A3 (en) Recombinant vibrio cholerae exotoxins
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MX2010007490A (es) Preparacion de derivados de sulfamida.
WO2011082245A3 (en) Metalloenzyme inhibitor compounds
WO2012064943A3 (en) Metalloenzyme inhibitor compounds
WO2008066784A3 (en) Expression of foxp3 by cancer cells
IL201509A0 (en) sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
WO2010039461A3 (en) Methods for synthesis and uses of inhibitors of ghrelin o-acyltransferase as potential therapeutic agents for obesity and diabetes
WO2007117687A3 (en) Implants for the treatment of dopamine associated states
WO2008002855A8 (en) Methods for the treatment of wounds
WO2008067408A3 (en) Method of isolating and propagating stem cells from benign tumors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2720616

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 588435

Country of ref document: NZ

Ref document number: 2009730771

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011503304

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12937029

Country of ref document: US

Ref document number: 2009235931

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009235931

Country of ref document: AU

Date of ref document: 20090407

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09730771

Country of ref document: EP

Kind code of ref document: A2